VKTX
Next earnings: Jul 29, 2026 · After close
Signal
Bullish Setup2
Price
1
Move+5.87%Strong session
Volume
1
Volume1.1× avgNormal activity
Technical
1
RSIRSI 51Momentum positive
PRICE
Prev Close
30.00
Open
30.25
Day Range29.65 – 32.42
29.65
32.42
52W Range22.96 – 43.15
22.96
43.15
44% of range
VOLUME & SIZE
Avg Volume
2.6M
FUNDAMENTALS
P/E Ratio
-7.7x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
1.20
Market-like
Quick Read
TrendInsufficient MA data
Momentum
BEARISH
thin 0% gross margin
Valuation
FAIR
P/E not available
Health
MODERATE
CR 5.7 · FCF negative
Neutral
Key MetricsTTM
Market Cap$3.68B
Revenue TTM$0.00
Net Income TTM-$472.33M
Free Cash Flow-$340.33M
Gross Margin0.0%
Net Margin0.0%
Operating Margin0.0%
Return on Equity-71.3%
Return on Assets-77.7%
Debt / Equity0.00
Current Ratio5.72
EPS TTM$-4.09

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.

Health Radar
3 strong3 concern
46/100
Liquidity
5.72Strong
Leverage
0.00Strong
Coverage
-15687.4xConcern
ROE
-71.3%Concern
ROIC
-100.0%Concern
Cash
$166MStrong
ANALYST COVERAGE24 analysts
BUY
+216.4%upside to target
L $95.00
Med $100.50consensus
H $107.00
Strong Buy
14%
Buy
2292%
Hold
14%
23 Buy (96%)1 Hold (4%)0 Sell (0%)
Full report →
Stock Health
Composite Score
3 of 4 signals bullish
8/10
Technicals
RSI RangeRSI 51 — Bullish momentum
Fundamentals
Last EarningsMissed estimates
Analyst ConsensusBuy
LiquidityCurrent Ratio 5.72 — healthy liquidity

1 signal unavailable — limited data for this stock

Upcoming Events
EEarnings Report · After CloseMay 6, 2026
Tomorrow
DEx-Dividend DateAug 3, 2026
In 90 days
PDividend PaymentAug 20, 2026
In 107 days
Technicals
Technical SetupBEARISH
Technicals →

Trend

DowntrendDeath Cross · 50D trails 200D by 0.7%

-0.4% vs SMA 50 · -1.1% vs SMA 200

Momentum

RSI50.8
Neutral territory
MACD-0.23
Below zero — bearish pulse · compressing
Market Position
Price Levels
52W High
$43.15+35.9%
EMA 50
$32.68+2.9%
Current
$31.76
EMA 200
$31.24-1.6%
52W Low
$22.96-27.7%
52-Week RangeMid-range
$22.9644th %ile$43.15
Earnings & Analysts

ANALYST ESTIMATES

Consensus of 13 analysts
Analyst revisions:EPS↑ Revised UpRevenue↓ Revised Down

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2025
$1.5M
$1.5M$1.5M
-$2.72
±9%
High13
FY2026(current)
$7.2M
$7.2M$7.2M
+387.4%-$4.68
±26%
High9
FY2027
$7.3M
$7.3M$7.3M
+2.5%-$4.62
±48%
High13
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryVKTX
Last 8Q
-17.7%avg beat
Beat 2 of 8 quartersMissed 6 Estimates falling
+23%
Q3'24
+8%
Q4'24
-14%
Q1'25
-21%
Q2'25
-32%
Q3'25
-16%
Q4'25
-55%
Q1'26
-36%
Q2'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced height
Analyst Activity
All ratings →
No recent activity
Raymond JamesStrong Buy
May 16
UPGRADE
Insider Activity
SEC Filings →
1 Buy/5 SellsNet Selling
Aubuchon Neil Willi…Chief Commerci…
$150K
Mar 10
BUY
Zante GregCFO
$1.0M
Jan 5
SELL
Zante GregCFO
$464K
Jan 5
SELL
Zante GregCFO
$353K
Jan 5
SELL
Zante GregCFO
$48K
Jan 5
SELL
Mancini MariannaCOO
$1.0M
Jan 5
SELL
Financials

INSTITUTIONAL OWNERSHIP

1
Pictet Asset Management Holding SA
696K
2
PRINCIPAL FINANCIAL GROUP INC
525K
3
Concurrent Investment Advisors, LLC
348K
4
WASATCH ADVISORS LP
313K
5
Nuveen, LLC
199K
6
OPPENHEIMER & CO INC
150K
7
RFG Advisory, LLC
142K
8
Quantum Private Wealth, LLC
105K
News & Activity

VKTX News

20 articles · 4h ago

About

novel therapeutics for metabolic and endocrine disorders.

Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Brian Lian
Kenneth HermanSenior Vice President of Commercial, Marketing & Sales
Michael MorneauVice President of Finance & Administration
Katherine MercierVice President of Quality and Compliance